肝素酶基因的差异性表达与肺癌的病理类型、分期、分化与转移研究  

Heparin enzyme gene difference expression and lung cancer pathology type, phased and splitting up and shifting to study

作　　者：李遂莹[1] 高夏[1] 袁五营[1] 孙芳[1] 王济森 李大军 聂志鸿 乔保安 

机构地区：[1]河南省胸科医院胸外科,河南郑州450008 [2]河南省济源市第一人民医院胸外科,河南济源454650

出　　处：《河南医学研究》2005年第3期224-226,共3页Henan Medical Research

基　　金：河南省科技攻关计划项目;编号:0424410019。

摘　　要：目的:探讨肝素酶mRNA在非小细胞肺癌(non_small cell lung cancer,NSCLC)中的差异性表达及其临床和病理学特征。方法:分别选取100例肺癌(实验组)和60例肺良性病变(对照组)手术标本,用逆转录PCR检测肝素酶mRNA。结果:①肝素酶mRNA在NSCLC中表达率均高于良性病变肺组织(P<0.01)。②肝素酶mRNA表达率在淋巴结转移组,Ⅲ期+Ⅳ期组、低分化组、腺癌组、肿瘤最大直径≥5 cm组分别高于无淋巴结转移组、Ⅰ期+Ⅱ期组、鳞癌组、肿瘤最大直径<5 cm组(P<0.05)。③肝素酶mRNA表达率在不同性别、年龄组比较,差异无显著性(P>0.05)。结论:肝素酶参与了NSCLC侵袭转移过程,可作为评估肺癌的恶性程度、转移潜力以及判断预后的一个新的标记物。Objective： Probe into the heparin enzyme mRNA difference expression and clinic and pathology characteristic in the non-little cell cancer. Methods： Choose 100 cases of lung cancer （experiment group ） and operation sample of benign pathological change of 60 lungs （contrast the group ） separately, use and measure heparin enzyme mRNA against duplicating PCR. Results： ①Heparin enzyme mRNA expresses and higher than the benign sick lung tissue in （NSCLC）（ P 〈 0. 01 ）. ②The enzyme mRNA expressing rate of heparin to split up group, gland cancer shifts the group in the lymph gland, Ⅳ issues of ＋ Ⅴ issue, the low group, tumour diameter not large most 〉 higher than not there is no lymph gland to last group, Ⅰ issues of ＋ Ⅱ issues of group, scale cancer group , getting heavier mosting 5 cm group separately 〈 5 cm（ P 〈 0.05）. ③The enzyme mRNA expressing rate of heparin is compared in different sex, age group, the difference has no significance （ P 〉 0. 05）. Conclusion ： Heparinenzyme participate in lung cancer attack the whole course that shift , can shift potentiality and new mark thing of prognosis , as malignant degree to assess lung cancer.

关 键 词：肺肿瘤 肝素酶 逆转录聚合酶链反应 

分 类 号：R735.7[医药卫生—肿瘤]